Valence 標誌
熱門
登入

加入到自選清單
專業圖表

Eli Lilly and

NYSE: LLY · 即時價格 · USD
1,180.16
-27.11 (-2.25%)
收盤時： Aug 14, 2026, 3:59 PM
1,180.00
-0.01%
盤後: 7:59 PM

Eli Lilly and (LLY) Stock Price, Analysis & Data

-2.25%
買價n/a
市值1.05T
營收 (ttm)79.67B
淨利（ttm）26.71B
貝塔0.51
EPS (ttm)29.74
本益比（ttm）40.65
正向 PE24.93
P/B (ttm)33.80
P/S (ttm)13.20
Earnings DateOct 29, 2026
賣價n/a
成交量2,115,056
20 日平均成交量3,002,886
打開1194.01
上一頁關閉1207.27
日間範圍1171.20 - 1199.00
52 週範圍685.15 - 1249.45
分析師Buy
目標價1344 (13.88%)
股利$6.92 (0.59%)
Ex-股利日期2026年8月14日

關於LLY

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabe...

[閱讀更多]
工業 Drug Manufacturers - General
部門 Healthcare
IPO 日期 Jun 1, 1972
員工 50,000
證券交易所 NYSE
股票代號 LLY
網站 https://www.lilly.com
完整的公司簡介

財務表現

Eli Lilly and 在 2025 年的營收為 65.18B，較前一年的 45.04B 增加 44.7%。 淨利為 20.64B，較前期增加 94.9%。

財務報表

分析師預測

根據27 分析師評等，LLY股票的平均評等為「Buy」。 12個月股價預測為1344，與最新價格相比為上漲空間的13.88%。

股票預測

獲利驚喜

Eli Lilly and 已於 Aug 5, 2026 公布季度財報：
  • 營收的 $22.97B 錯過估計 $0, 與 47.67% YoY 成長.
  • EPS 的 8.38 超出估計 1.80, 與 32.81% YoY 成長.

    • 下次財報發布

    Eli Lilly and 定於發布財報 Oct 29, 2026, 開市前。
    分析師預估營收 ... 升級
    news image

    4 小時 前 · Insider Monkey

    Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth

    On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for “agentic c...

    news image

    6 小時 前 · Motley Fool

    GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

    They are way more than just GLP-1 stocks.

    news image

    8 小時 前 · Trefis

    AbbVie Defends Its Turf, But Leaves One Big Question Open

    AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

    news image

    11 小時 前 · 24/7 Wall St.

    Vanguard Quietly Changed the Index Behind Your VUG ETF. Here’s What Happens to Your Portfolio

    Vanguard swapped the benchmark powering one of the most popular growth ETFs on the market, and most holders never saw it coming. What looks like a paperwork formality could quietly reshape which compa...

    news image

    13 小時 前 · Simply Wall St.

    Eli Lilly (LLY) Steps Up Legal Fight Over Illegal Retatrutide Sales

    Eli Lilly (NYSE: LLY) has intensified legal action against U.S. entities accused of selling unauthorized versions of its experimental obesity drug retatrutide. The company is pursuing multiple lawsuit...

    第 1 頁，共 2 頁